leisure time -WSS

leisure time

author：fashion 2025-09-28 01:35:00 - browse：36

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： PhRMA lawsuit over Medicare drug price negotiation tossed

entertainment

leisure time

WSS

The Readout: Gilead, Bernie Sanders, and other pharma news

IRA could hurt research into orphan drugs for rare diseases

Robert F. Kennedy is pitching centrism on health, even on abortion

FDA approves updated Covid vaccines

New weight loss drugs vying to be the next Wegovy or Mounjaro

Medicare threatens to cut off funding for HCA's Mission hospital

focus

leisure time

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: How biotech is using artificial intelligence

Drug repurposing or repositioning? The language matters

Food makers to regulators: Ultra

Malaria cases in Florida and Texas: Here’s what you need to know

What to make of Biden’s latest efforts on cancer research

Trump demands the U.S. pay no more for drugs than other countries … again

PEPFAR is under serious threat — and so is global health

Bright Health sells Medicare Advantage business to Molina

FDA proposes changes to key medical devices approval pathway

explore

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medical mystery: When a cough is not just a cough

FDA proposes changes to key medical devices approval pathway

To avoid data mishandling cases, universities eye AI and other tools

Will the IRA bring competition to the biologics market?

A disappointing year of Humira biosimilars

entertainment

leisure time

entertainment

focus